TuisBMY • NYSE
add
Bristol-Myers Squibb Co
Vorige sluiting
$61,10
Dagwisseling
$61,18 - $62,68
Jaarwisseling
$42,52 - $63,33
Markkapitalisasie
127,01Â mjd USD
Gemiddelde volume
13,17Â m
P/V-verhouding
18,03
Dividend-opbrengs
4,04%
PrimĂŞre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 12,50Â mjd | 1,30% |
Bedryfskoste | 5,47Â mjd | -13,56% |
Netto inkomste | 1,09Â mjd | 1Â 409,72% |
Netto winsgrens | 8,69 | 1Â 398,28% |
Wins per aandeel | 1,26 | -24,55% |
EBITDA | 4,54Â mjd | -2,17% |
Effektiewe belastingkoers | 26,12% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 10,67Â mjd | -1,71% |
Totale bates | 90,04Â mjd | -2,77% |
Totale aanspreeklikheid | 71,53Â mjd | -6,14% |
Totale ekwiteit | 18,51 mjd | — |
Uitstaande aandele | 2,04 mjd | — |
Prys om te bespreek | 6,74 | — |
Opbrengs op bates | 9,42% | — |
Opbrengs op kapitaal | 13,01% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,09Â mjd | 1Â 409,72% |
Kontant van bedrywe | 1,97Â mjd | -55,53% |
Kontant van beleggings | -1,46Â mjd | -643,88% |
Kontant van finansiering | -6,03Â mjd | -267,17% |
Netto kontantverandering | -5,51Â mjd | -324,45% |
Beskikbare kontantvloei | 669,62Â m | -84,21% |
Meer oor
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
Gestig
1887
Webwerf
Werknemers
32Â 500